CEP-33457
C33457/2047
Phase 3 small_molecule completed
Quick answer
CEP-33457 for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed